{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Summary statistics are not presented as geometric means were not calculated if fewer than 3 participants had reportable values.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Apparent Clearance (CL/F) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to SC arm.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06671008 was administered as a weekly subcutaneous (SC) injection in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 5 cycles in this cohort.","id":"OG000","title":"PF-06671008 200 ng/kg SC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest and who had no major protocol deviations influencing the PK assessment.","reportingStatus":"POSTED","timeFrame":"C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose","title":"Apparent Clearance (CL/F) of PF-06671008","type":"SECONDARY","unitOfMeasure":"mL/hr/kg"}